Richard B. Lipton, MD, a professor of neurology at Albert Einstein College of Medicine, discussed the connections between depression, anxiety, and calcitonin gene-related peptide (CGRP)-targeted therapies for migraine prevention in a recent interview. He emphasized the clinical significance of these findings, particularly for treatment planning.

Read More

Dr. Lipton highlighted that individuals with migraine are often at a higher risk for both depression and anxiety. He noted that the relationship between migraine and depression is bidirectional; migraines can lead to increased rates of depression, and depression can also manifest in the form of migraines. Recent studies he assessed suggest that treating migraine effectively may alleviate depressive symptoms as well.

His analysis showed consistent reductions in depressive and anxiety symptoms following migraine treatment, emphasizing that some CGRP therapies, like fremanezumab, have shown significant benefits for patients who have both migraine and depression. Dr. Lipton stated that in such populations, addressing migraines can lead to substantial improvements in both headache and mood disorders.

One of the major challenges identified is the overlap between neurologists and psychiatrists in recognizing these comorbid conditions. Dr. Lipton stressed the importance of screening migraine patients for depression and vice versa. He indicated that about 15% of migraine patients experience depression, and this figure rises to 30% in those with chronic migraines.

For management, Dr. Lipton advocates using screening tools like the PHQ-9 to assess depression in migraine patients. Regarding treatment priorities, he advises clinicians to consider the symptoms causing the most disability and patient preferences when deciding whether to address migraine, depression, or both simultaneously. Previously, medications like tricyclic antidepressants and SNRIs were used to manage both conditions, but CGRP therapies might simplify treatment by simultaneously alleviating both migraine and mood disorders.

In the discussion about study methodologies, Dr. Lipton explained that while randomized trials provide control groups, observational studies offer real-world insights into treatment efficacy. He believes both approaches are valuable for understanding how CGRP-targeted therapies can influence mental health outcomes.

Looking ahead, Dr. Lipton noted the need for future research to clarify the mechanisms by which CGRP therapies affect depression. He suggested exploring whether improvements in mood are due to reductions in migraine frequency, enhanced self-efficacy, or other factors.

The key takeaways for clinicians involve assessing both migraine and mood disorders in patients and considering treating migraine as a priority, particularly when depression is mild or moderate. For patients with severe depression or suicidal ideation, it is crucial to address psychiatric issues as a priority.

For reference, the findings were documented in an analysis by Al-Sayegh et al. in the journal Cephalalgia.